Abeona Therapeutics reported a Q3 net ZEVASKYN revenue of $13.5 million and expanded its national qualified treatment center network to eight sites. The company also announced the acquisition of a Phase 3-ready asset, APT-1011, for eosinophilic esophagitis, as it shifts toward a diversified commercial-stage business model.